So with Pharmac, we discussed the interim observations from the independent review of Pharmac and asked what progress that Pharmac was making towards addressing some of those issues raised. So what Pharmac told us was that they were seeking more consumer engagement at an earlier stage in its processes, that they'd established a Māori advisory rōpū, and had increased Māori and Pacific representation in its consumer advisory group and other statutory committees—so, basically, a real focus on engagement. In terms of the criticisms that it was reluctant to share information with shareholders and the public, what Pharmac pointed out was that a lot of commercial agreements with suppliers had confidentiality agreements, but it was able to develop processes that allowed it to provide data to the review panel without breaching any of those agreements with suppliers.